Revenue (Tables)

9 Months Ended

Jan. 24, 2020

Revenue from Contract with Customer [Abstract]

The table below illustrates net sales by segment and division for the three and nine months ended January 24, 2020 and January 25, 2019:


	Three months ended⁽¹⁾						Nine months ended⁽¹⁾
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Cardiac Rhythm & Heart Failure	$	1,393	$	1,397	$	4,201	$	4,295
Coronary & Structural Heart	948		913		2,844		2,736
Aortic, Peripheral, & Venous	478		476		1,420		1,424
Cardiac and Vascular Group	2,819		2,786		8,464		8,455
Surgical Innovations	1,474		1,434		4,345		4,224
Respiratory, Gastrointestinal, & Renal	702		690		2,073		1,999
Minimally Invasive Therapies Group	2,176		2,124		6,418		6,223
Brain Therapies	795		732		2,307		2,107
Spine	674		655		2,023		1,963
Specialty Therapies	340		325		996		956
Pain Therapies	303		314		910		942
Restorative Therapies Group	2,111		2,026		6,235		5,968
Diabetes Group	610		610		1,798		1,765
Total	$	7,717	$	7,546	$	22,916	$	22,411

(1) Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum.

During the first quarter of fiscal year 2020, the Company realigned its divisions within the Restorative Therapies Group, which included a movement of revenue from Transformative Solutions product lines previously included in Specialty Therapies to a product line under Brain Therapies. As a result, net sales for fiscal year 2019 have been recast to adjust for this realignment.

The table below illustrates net sales by market geography for each segment for the three and nine months ended January 24, 2020 and January 25, 2019:


	U.S.⁽¹⁾⁽⁴⁾						Non-U.S. Developed Markets⁽²⁾⁽⁴⁾						Emerging Markets⁽³⁾⁽⁴⁾
	Three months ended						Three months ended						Three months ended
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Cardiac and Vascular Group	$	1,366	$	1,369	$	915	$	924	$	538	$	493
Minimally Invasive Therapies Group	934		930		791		796		451		398
Restorative Therapies Group	1,409		1,354		436		435		266		237
Diabetes Group	312		348		236		213		63		49
Total	$	4,021	$	4,001	$	2,377	$	2,368	$	1,318	$	1,177

	U.S.⁽¹⁾⁽⁴⁾						Non-U.S. Developed Markets⁽²⁾⁽⁴⁾						Emerging Markets⁽³⁾⁽⁴⁾
	Nine months ended						Nine months ended						Nine months ended
(in millions)	January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019		January 24, 2020		January 25, 2019
Cardiac and Vascular Group	$	4,182	$	4,240	$	2,735	$	2,766	$	1,547	$	1,449
Minimally Invasive Therapies Group	2,769		2,659		2,364		2,396		1,285		1,168
Restorative Therapies Group	4,187		4,005		1,278		1,275		770		688
Diabetes Group	930		1,006		693		619		176		140
Total	$	12,068	$	11,910	$	7,069	$	7,056	$	3,778	$	3,445

(1)U.S. includes the United States and U.S. territories.

(2)Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.

(3)Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.

(4)Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum.